Review article: The functional abdominal pain syndrome

Alimentary Pharmacology and Therapeutics

Volumn 33, Issue 5, 2011, Pages 514-524

  Sperber, A D ^a,b   Drossman, D A ^c  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; DESIPRAMINE; DULOXETINE; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; NARCOTIC ANALGESIC AGENT; NORTRIPTYLINE; PAROXETINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ABDOMINAL PAIN; ADL DISABILITY; COGNITIVE THERAPY; DEFECATION HABIT; DISEASE DURATION; DISEASE SEVERITY; DISTRESS SYNDROME; DOCTOR PATIENT RELATION; DRUG RECEPTOR BINDING; FEEDING BEHAVIOR; FUNCTIONAL ABDOMINAL PAIN SYNDROME; HUMAN; IRRITABLE COLON; LABORATORY TEST; MEDICAL LITERATURE; NEUROMODULATION; NEUROPATHIC PAIN; PAIN THRESHOLD; PATHOPHYSIOLOGY; PATIENT ATTITUDE; PHYSICAL EXAMINATION; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW;

ABDOMINAL PAIN; ANTIDEPRESSIVE AGENTS; DECISION MAKING; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; MALE; PAIN MEASUREMENT; PATIENT ACCEPTANCE OF HEALTH CARE; PHYSICIAN-PATIENT RELATIONS; PSYCHOPHYSIOLOGIC DISORDERS; SEVERITY OF ILLNESS INDEX; SEX FACTORS; SYNDROME;

EID: 79251515498     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04561.x     Document Type: Review

References (43)

1. Drossman DA,. The functional gastrointestinal disorders and the Rome III process. In:, Drossman DA, Corazziari E, Delvaux M, Spiller RC, Talley NJ, Thompson WG, et al., eds. Rome III. The Functional Gastrointestinal Disorders, 2nd edn. McLean, VA: Degnon Associates, Inc., 2006: 1-29.
2. Clouse RE, Mayer EA, Aziz Q, et al. Functional abdominal pain syndrome. In:, Drossman SA, Corazziari E, Delvaux M, Spiller RC, Talley NJ, Thompson WG, et al., eds. Rome III. The Functional Gastrointestinal Disorders, 3rd edn. McLean, Virginia: Degnon Associates, Inc., 2006: 557-93.
3. Drossman DA,. Presidential Address: gastrointestinal illness and the biopsychosocial model. Psychosom Med 1998; 60: 258-67.
4. Longstreth GF, Drossman DA,. Severe irritable bowel and functional abdominal pain syndromes: managing the patient and health care costs. Clin Gastroenterol Hepatol 2005; 3: 397-400.
5. Drossman DA, Li Z, Andruzzi E, et al. U.S. householder survey of functional GI disorders: prevalence, sociodemography and health impact. Dig Dis Sci 1993; 38: 1569-80.
6. Thompson WG, Irvine EJ, Pare P, Ferrazzi S, Rance L,. Functional gastrointestinal disorders in Canada: first population-based survey using Rome II criteria with suggestions for improving the questionnaire. Dig Dis Sci 2002; 47: 225-35.
7. Boyce PM, Koloski NA, Talley NJ,. Irritable bowel syndrome according to diagnostic criteria: are the new Rome II criteria unnecessarily restrictive for research and practice? Am J Gastroenterol 2000; 95: 3176-83.
8. Sperber AD, Shvartzman P, Friger M, Fich A,. Unexpectedly low prevalence rates of IBS among adult Israeli Jews. Neurogastroenterol Motil 2005; 17: 207-11.
9. Sperber AD, Shvartzman P, Friger M, Fich A,. A comparative reappraisal of the Rome II and Rome III diagnostic criteria: are we getting closer to the 'true' prevalence of irritable bowel syndrome? Eur J Gastroenterol Hepatol 2007; 19: 441-7.
10. Maxton DG, Whorwell PJ,. Use of medical resources and attitudes to health care of patients with "chronic abdominal pain". Br J Med Econ 1992; 2: 75-9.
11. Casey KL,. Match and mismatch: identifying the neuronal determinants of pain. Ann Intern Med 1996; 124: 995-8.
12. Wood JD,. Functional abdominal pain: the basic science. J Pediatr Gastroenterol Nutr 2008; 47: 688-93.
13. Dorn SD, Palsson OS, Thiwan SI, et al. Increased colonic pain sensitivity in irritable bowel syndrome is the result of an increased tendency to report pain rather than increased neurosensory sensitivity. Gut 2007; 56: 1202-9.
14. Nozu T, Kudaira M,. Altered rectal sensory response induced by balloon distention in patients with functional abdominal pain syndrome. Biopsychosoc Med 2009; 3: 13.
15. Sperber AD, Blank Morris C, Greemberg L, et al. Development of abdominal pain and IBS following gynecological surgery: a prospective, controlled study. Gastroenterology 2008; 134: 75-84.
16. Ringel Y, Drossman DA, Leserman JL, et al. Effect of abuse history on pain reports and brain responses to aversive visceral stimulation: an FMRI study. Gastroenterology 2008; 134: 396-404.
17. Drossman DA, Ringel Y, Vogt BA, et al. Alterations of brain activity associated with resolution of emotional distress and pain in a case of severe irritable bowel syndrome. Gastroenterology 2003; 124: 754-61.
18. Jones MP, Dilley JB, Drossman D, Crowell MD,. Brain-gut connections in functional GI disorders: anatomic and physiologic relationships. Neurogastroenterol Motil 2006; 18: 91-103.
19. Sperber AD, Drossman DA,. Functional abdominal pain syndrome: constant or frequently recurring abdominal pain. Am J Gastroenterol 2010; 105: 770-4.
20. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC,. Functional bowel disorders. Gastroenterology 2006; 130: 1480-91.
21. Tack J, Talley NJ, Camilleri M, et al. Functional gastroduodenal disorders. Gastroenterology 2006; 130: 1466-79.
22. Behar J, Carazziari E, Guelrud M, Hogan WJ, Sherman S, Toouli J,. Functional gallbladder and sphincter of Oddi disorders. Gastroenterology 2006; 130: 1498-509.
23. Carnett JB,. Intercostal neuralgia as a cause of abdominal pain and tenderness. Surg Gynecol Obstet 1926; 42: 625.
24. First HB, Frances A, Pincus HA,. DSM-IV-TR Guidebook. Washington, DC: American Psychiatric Publishing, 2004.
25. Drossman DA,. Challenges in the physician-patient relationship: feeling "drained". Gastroenterology 2001; 121: 1037-8.
26. Drossman DA, Toner BB, Whitehead WE, et al. Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology 2003; 125: 19-31.
27. Gonsalkorale WM, Houghton LA, Whorwell PJ,. Hypnotherapy in irritable bowel syndrome: a large-scale audit of a clinical service with examination of factors influencing responsiveness. Am J Gastroenterol 2002; 97: 954-61.
28. Creed F, Fernandes L, Guthrie E, et al. The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome. Gastroenterology 2003; 124: 303-17.
29. Grover M, Drossman DA,. Psychopharmacologic and behavioral treatments for functional gastrointestinal disorders. Gastrointest Endosc Clin N Am 2009; 19: 151-70.
30. Drossman DA,. Medicine has become a business. But what is the cost? Gastroenterology 2004; 126: 952-3.
31. Grunkemeier DM, Cassara JE, Dalton CB, Drossman DA,. The narcotic bowel syndrome: clinical features, pathophysiology, and management. Clin Gastroenterol Hepatol 2007; 5: 1126-39.
32. Drossman DA,. Severe and refractory chronic abdominal pain: treatment strategies. Clin Gastroenterol Hepatol 2008; 6: 978-82.
33. Agostini S, Eutamene H, Cartier C, et al. Evidence of central and peripheral sensitization in a rat model of narcotic bowel like-syndrome. Gastroenterology 2010; 139: 553-63.
34. Thiwan S, Drossman DA, Morris CB, et al. Not all side effects associated with tricyclic antidepressant therapy are true side effects. Clin Gastroenterol Hepatol 2009; 7: 446-51.
35. McQuay HJ, Tramer M, Nye BA, Carroll D, Wiffen PJ, Moore RA,. A systematic review of antidepressants in neuropathic pain. Pain 1996; 68: 217-27.
36. Ford AC, Talley NJ, Schoenfeld PS, Quigley EMM, Moayyedi P,. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut 2009; 58: 367-78.
37. Drossman DA,. Beyond tricyclics: new ideas for treating patients with painful and refractory functional gastrointestinal symptoms. Am J Gastroenterol 2009; 104: 2897-902.
38. Perera TD, Park S, Nemirovskaya Y,. Cognitive role of neurogenesis in depression and antidepressant treatment. Neuroscientist 2008; 14: 326-38.
39. Valet M, Gundel H, Sprenger T, et al. Patients with pain disorder show gray-matter loss in pain-processing structures: a voxel-based morphometric study. Psychosom Med 2009; 71: 49-56.
40. Brunoni AR, Lopes M, Fregni F,. A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression. Int J Neuropsychopharmacol 2008; 11: 1169-80.
41. Clouse RE, Lustman PJ,. Use of psychopharmacological agents for functional gastrointestinal disorders. Gut 2005; 54: 1332-41.
42. Grover M, Dorn SD, Weinland SR, Dalton CB, Gaynes BN, Drossman DA,. Atypical antipsychotic quetiapine in the management of severe refractory functional gastrointestinal disorders. Dig Dis Sci 2009; 54: 1284-91.
43. Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006; 354: 1243-52.